Ortanol (Esomeprazole)

Ortanol (esomeprazole) acts on acid‑related gastrointestinal conditions, providing symptom relief and mucosal healing.

• Gastro‑oesophageal reflux disease (GERD): reduces reflux episodes and promotes healing of esophageal erosions.
• Peptic ulcer disease: supports ulcer healing by decreasing gastric acid secretion.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑producing tumors.
• Erosive esophagitis: aids in the resolution of inflammation and ulceration of the esophageal lining.
• Helicobacter pylori eradication regimens (as adjunctive therapy): enhances the effectiveness of antibiotic‑based regimens.

• Esomeprazole selectively and irreversibly inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By blocking this final step of acid production, it markedly lowers gastric acidity, allowing damaged mucosa to heal and reducing reflux‑related symptoms.

Adverse reactions to esomeprazole are generally mild to moderate and vary with individual tolerance.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhea: loose stools occurring during early treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild discomfort in the stomach area.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: severe diarrhea with abdominal pain.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: signs of hepatic stress.
• Acute interstitial nephritis: kidney inflammation presenting with fever and urinary changes.

When prescribing Ortanol, clinicians should consider several safety aspects.

• Assess renal function: adjust use in patients with severe impairment.
• Evaluate hepatic status: use with caution in liver disease.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: watch for bone density loss and magnesium deficiency.
• Pregnancy and lactation: weigh benefits against potential risks.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Esomeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Ketoconazole: reduced absorption leading to therapeutic failure.
• Atazanavir: decreased plasma concentrations compromising antiviral efficacy.
• Warfarin: potential increase in anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Clopidogrel: possible reduction in antiplatelet activity.
• Digoxin: modest increase in serum levels.
• Methotrexate: elevated exposure, especially at high doses.
• Phenytoin: altered metabolism requiring dose adjustment.